Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management.

摘要

This pooled analysis of seven German studies of 6377 patients treated with taxane-anthracycline-based neoadjuvant systemic chemotherapy indicates that, although pathologic complete response (pCR) is regarded as a surrogate end point of neoadjuvant systemic chemotherapy, it is not representative of outcome in all breast cancer subtypes. Patients who achieved a pCR (no residual cancer in the breast and the lymph nodes) had the lowest risk of disease recurrence, compared with those who had in situ or invasive cancer and/or involved nodes. While the presence of pCR was related to excellent outcome in the overall population, different outcomes were observed when subgroup analysis according to breast cancer subtypes was performed. In the low-proliferating